AVBP ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc. (AVBP) is expected to report earnings on November 11, 2026, after the market close. The consensus earnings estimate is a loss of $1.04 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -4.0% since its last earnings release on August 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About ArriVent BioPharma, Inc.
ArriVent BioPharma Inc. is a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent BioPharma Inc. is based in NEWTOWN SQUARE, Pa.
Sector
Healthcare
Industry
Biotechnology